AgomAb Therapeutics NV (AGMB)
AGMB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AGMB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Belgium |
| IPO year | 2026 |
| SEC CIK | 0002020932 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Belgium |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Based on the above and the actions the Company has taken, management has concluded that the substantial doubt about its ability to continue as a going concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis." | 20-F 2026-04-23 |
| Cash and burn | $95.5M cash; operating cash flow -$14.3M a quarter. | Report 2025-12-31 |
| Shares outstanding | 34,167,168 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers Reviseurs d'Entreprises, Diegem, Belgium | PCAOB Form AP 2026-05-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$69.1M | -$57.2M | $95.5M | No debt tags | Needs four quarters | 20-F 2026-04-23 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-02-06 |
| Latest annual report FORM 20-F | 20-F | 2026-04-23 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 51 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -16.8% |
| 1 month | -27.8% |
| 3 months | -54.4% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -64.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
| EIKN | Eikon Therapeutics Inc. | $5.38 | -9.95% | $291.8M |
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
| KYTX | Kyverna Therapeutics Inc. | $4.76 | -5.74% | $300.9M |
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.14 | -2.56% | $303.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier